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Abstract
Preclinical data showed anticancer effects of statins in melanoma, but meta-analy-
ses could not demonstrate a reduced melanoma incidence in statin users. Rather
than preventing occurrence, statins might reduce growth and metastatic spread of
melanomas and ultimately improve survival. In this population-based study, we
investigated the relationship between statin use and survival of melanoma
patients. Patients ≥18 years who were diagnosed with cutaneous melanoma (Bre-
slow thickness >1 mm) and registered in the Eindhoven Cancer Registry and in
PHARMO Database Network between 1 January 1998 and 31 December 2010
were eligible. The hazard ratio (HR) of all-cause mortality was calculated by
employing adjusted time-dependent and time-fixed Cox proportional hazard
models. Disease-specific survival was estimated by means of 3-year relative sur-
vival rates (RSR). A control cohort of randomly selected patients using statins
from PHARMO Database Network matched on age and gender was used to com-
pare RSR of statin users to the general population. After melanoma diagnosis, 171
of 709 patients used statins. Use of statins showed a nonsignificantly decreased
hazard of death (adjusted HR 0.76, 95% confidence interval [CI] 0.50–1.61). After
stratification for gender, male but not female statin users showed a favorable out-
come compared to nonusers (HR 0.57, 95% CI 0.32–0.99; HR 1.22, 95% CI 0.62–
2.38, respectively). Three-year RSR for male statin users tended to be higher than
for nonusers (91% vs. 80.5%, P = 0.06), no differences were observed in women
(87.1% vs. 92.5%, P = 0.76). Statin use was not associated with an improved sur-
vival of melanoma patients. The trend for better survival of male in contrast to
female statin users warrants further research.
Introduction
Melanoma is the deadliest form of skin cancer and respon-
sible for 80% of skin cancer deaths [1]. Results from a
recent analysis predict a continuous melanoma incidence
rise in Europe, especially in the Nordic and north-western
European countries [2]. Despite novel treatment options
[3, 4], melanoma—once metastasized beyond locoregional
sites—is incurable in most patients.
Statins are frequently used to prevent cardiovascular dis-
eases and block the enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, which catalyzes the
conversion of HMG-CoA to mevalonate, the rate-limiting
step in de novo cholesterol synthesis [5]. They may also
have anticancer properties—either as a direct effect of the
lowered cholesterol levels leading to decreased proliferation
and migration of cancer cells [6, 7], a reduction in the
downstream products of the mevalonate pathway [8, 9], or
through other pleiotropic effects on the cellular level.
Particularly in melanoma, antiproliferative, proapoptot-
ic, and immunomodulatory effects of statins have been
shown in cell lines [10–14] and mouse models [14–17].
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Inhibition of the mevalonate metabolic pathway seems to
be one of the major factors as it is essential for membrane
formation and isoprenylation of several small GTPases
involved in cell growth and differentiation. Among the
GTPases requiring isoprenylation are the proteins of the
Rho family including RhoA, Rac1, and Cdc42, which reg-
ulate signal transduction from receptors in the membrane
in a variety of cellular events, thereby acting as molecular
switches in the cell [18]. Kidera et al. [15] could demon-
strate a significantly decreased membrane localization of
Rho proteins in simvastatin-treated melanoma cells com-
pared to the control cells. Additionally, oral administra-
tion of statins to mice significantly inhibited lung
metastasis [15]. Previously, atorvastatin was shown to
inhibit Rho activation in vitro and in vivo metastasis of
melanomas overexpressing RhoC, but did not affect cell
growth in vivo [19].
Large meta-analyses of randomized controlled trials,
however, could not find a significant association between
statin use and a lower melanoma incidence [20–22], but
population-based studies showed that statin use was asso-
ciated with a reduced Breslow thickness [23] and that
advanced melanomas were slightly more common among
nonstatin users [24].
Rather than preventing the formation of a primary
melanoma, statins might therefore reduce disease progres-
sion and/or melanoma-specific death as has been seen in
other cancers [25–27]. We decided to investigate the
effect of statins on overall survival in melanoma patients
in a large population-based cohort study in the Nether-
lands using data from the Eindhoven Cancer Registry
(ECR) and the PHARMO Database Network hypothesiz-
ing that statin use after melanoma diagnosis would result
in improved survival.
Patients and Methods
Study population and data collection
Data were retrieved from the linkage between the ECR
and the PHARMO Database Network assuring high-qual-
ity and extensive information on statin exposure and mel-
anoma diagnosis [28]. The ECR is a population-based
cancer registry in the South of the Netherlands covering
2.4 million inhabitants and includes more than 95% of all
newly diagnosed malignancies [29]. The registry is notified
by six pathology departments, ten community hospitals
(at 17 locations), and two large radiotherapy departments.
Trained registration clerks actively collect data on diagno-
sis, patient characteristics, comorbidity, staging, and
detailed information about initial treatment from hospital
medical records. Linkage with the Dutch municipal
records provided vital status until 31 December 2010.
PHARMO Database Network covers a demographic
region of three million inhabitants and is a network of
patient databases [28]. The central patient database is
linked to many databases [30]. Relevant databases for this
study include virtual complete longitudinal data obtained
from community pharmacies (outpatient), hospital dis-
charge records (Dutch National Medical Registration:
LMR), a mortality registration, and a growing number of
clinical laboratories, in-hospital pharmacies (inpatient),
and general practitioners (these last three databases are
available for a subcohort of the patients included in the
PHARMO Database Network) [28]. All pharmacy dis-
pensed healthcare products on the Dutch market pre-
scribed by medical practitioners are included in the
community pharmacy database. Drug-dispensing records
in PHARMO Database Network are virtually complete
with regard to prescription drugs as previous studies
demonstrated that most Dutch patients only visit one
pharmacy [31, 32].
A total of one million inhabitants are captured in the
overlapping PHARMO-ECR catchment area. Follow-up of
patients was either until patients moved away from the
PHARMO-ECR catchment area, end of data collection of
the specific community pharmacy, or end of study or
death, whichever occurred first.
Study population
Patients (≥18 years) registered in the ECR with a diagno-
sis of invasive cutaneous melanoma with a tumor thick-
ness >1 mm between 1 January 1998 and 31 December
2010 who were also registered in PHARMO Database
Network at the time of melanoma diagnosis were eligible
(N = 791) (Fig. 1).
A control cohort of 1100 randomly selected statin users
of the PHARMO Database Network cohort matched on
age, gender, and index date in a 1:10 ratio to the statin-
using melanoma patients was constructed to compare the
survival of statin users to the general population. The
date of melanoma diagnosis was used as the index date of
the matched controls (this required that the date of mela-
noma diagnosis of the melanoma patient had to be within
the follow-up time in PHARMO Database Network of the
matched control). The central bureau for genealogy, the
local pharmacy, or the hospital served as sources for the
date of death of the matched statin users.
A minimum of 1 year of follow-up in the PHARMO
Database Network was required for patients and controls
prior to melanoma diagnosis or index date, respectively,
to determine potential confounders and drug exposure in
the year prior to diagnosis, leaving 709 melanoma
patients and 511 control cases for final analyses. The date
of melanoma diagnosis (melanoma cohort) and the index
ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 1285
E. Livingstone et al. Statin Use and Melanoma Survival
date (matched cohort) corresponded with the start of fol-
low-up.
Statin use
Information on dispensing including anatomical thera-
peutical chemical (ATC) code, date dispensed, and days’
supply was obtained from the PHARMO Database Net-
work. Dispensings with the ATC code group C10AA
(HMG-CoA reductase inhibitors), C10BA (HMG-CoA
reductase inhibitors in combination with other lipid mod-
ifying agents) and C10BX (HMG-CoA reductase inhibi-
tors, other combinations) of the WHO Collaborating
Centre for Drug Statistics Methodology (Table 1) were
considered statin dispensings. For combination drugs,
only the statin was considered.
By dividing the amount of dispensed drug by the num-
ber of pills prescribed per day as defined in the pharmacy
data, the duration of each dispense was calculated. The
number of overlapping days was added to the dispensing
duration of the second dispensing, if two dispensings
overlapped. To be able to compare the dosage of different
types of statins, the defined daily dose system (DDD) of
the WHO [33] was used. For each individual patient, the
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Figure 1. Study population selection and matching. aEighty-two cases excluded as <1 year FU in PHARMO Database Network. bFive hundred
forty-six randomly selected statin users excluded as no long-term statin users, 43 cases excluded as <1 year FU in PHARMO Database Network.
Cstatin (≥2) dispensings in the year prior to and statin use at the time of melanoma diagnosis. ECR, Eindhoven Cancer Registry; FU, follow-up.
Table 1. Frequency of all dispensed statins in statin patients after
melanoma diagnosis (80.4% lipophilic).





Atorvastatin x 1361 28.7
Cerivastatin2 x 16 0.3
Fluvastatin x 187 3.9
Pravastatin x 575 12.1
Rosuvastatin x 356 7.5
Simvastatin x 2244 47.4
Total 4739 100
1Lovastatin, a commonly prescribed statin in many countries, is not on
the market in the Netherlands.
2Cerivastatin has been withdrawn from clinical use in 2001.
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amount of pills dispensed by the corresponding dosage
per pill and divided by the DDD.
Other covariates
The following variables were considered potential con-
founders: age at diagnosis, gender, histological subtype,
location of the primary melanoma, tumor thickness (cate-
gorical variable), nodal and distant metastases, and com-
orbidities (any and specific comorbidities). As a proxy of
general morbidity as well as a proxy of healthcare- and
pharmacy-seeking behavior, the number of distinct medi-
cation classes dispensed (unique ATC codes) excluding
statins and unique hospital admissions in the year prior
to diagnosis were also considered potential confounders
(both as continuous variables). All variables that were
considered potential confounders were also considered
potential effect modifiers and tested for interaction.
Statistical analysis
To compare relevant characteristics of users and nonusers,
v2 tests and Fisher’s exact tests were used for categorical
variables and Student’s t-test for continuous variables.
Cox proportional hazard (PH) models were used to ana-
lyze the association between statin use and survival. Time
since diagnosis was the underlying timescale.
Statin use before diagnosis was defined as having at
least two statin dispensings during the year prior to mela-
noma diagnosis and use of statins at the time of diagno-
sis. A time-varying covariate was used for statin use after
diagnosis, where patients were considered statin users
since first statin use after diagnosis. Duration and dose of
statin use after diagnosis were also taken into account as
time-varying covariates. In these analyses, the number of
cumulative days of statin use of the subject with the event
of interest is compared with the cumulative statin use of
all other subjects at the same time point. Covariates
which influenced the age and sex-adjusted HR by more
than 10% were considered potential confounders and
added in the multivariable analysis.
As information on cause of death was not accessible,
we calculated 3-year relative survival rates (RSRs) as a
proxy for disease-specific mortality. The RSR is the abso-
lute survival rate divided by the expected survival rate in
the period of diagnosis from the general population with
the same sex and age structure [34, 35]. By calculating
RSR for the statin-using and nonusing melanoma patient
groups, an estimate of melanoma-specific survival is being
made. Such an analysis is a good and valid alternative if
cause-specific death is not available and can sometimes
even be more accurate than estimating cause-specific sur-
vival by using death certificates because the primary cause
of death is often not clear and inter-doctor variation in
the cause of death ascertainment is common. As immortal
time bias [36] might occur when statin use after diagnosis
were investigated in the RSR calculations, statin use
before diagnosis was assessed using the aforementioned
definition. Graphs for time interval-specific hazard ratios
(HRs) were visually inspected and showed no violation of
the PH assumption. All statistical tests were two sided
with a rejection of the null hypothesis at P < 0.05. Analy-
ses were performed using SPSS 20.0 (IBM Corp.,
Armonk, NY) and SAS 9.3 (SAS Institute Inc., Cary, NC).
Results
Study population
The baseline characteristics are shown in Table 2 (refer to
Table S1 for characteristics stratified on gender). In total,
171 (24.1%) of the 709 eligible melanoma patients used
statins after melanoma diagnosis. During 2632 patient
years of follow-up, 159 patients died. Patients who used
statins were more likely to be male (58.5%), older (67.3
vs. 58.0 years), and to have a longer follow-up time
(3.5 years vs. 2.9 years) than nonusers. There was no sig-
nificant difference for tumor thickness or nodal or distant
metastasis status between groups (Table 2). Comorbidities,
hospitalizations, and medication use were more prevalent
in the statin user group as expected. The higher rate of
distant metastases of female statin users at initial diagnosis
(4.2%) compared to males (0% for statin users and 2.6%
for nonusers) and to female nonusers (1.9%) was statisti-
cally nonsignificant and is possibly influenced by the low
numbers of patients with distant metastases in general.
Female patients with statin use have a higher rate of other
cancers compared to males and to female nonusers.
Patient and tumor characteristics of the cohort with
statin use before melanoma diagnosis were very similar
and presented in Table S2.
Statin use and HRs of all-cause death
Almost half of all dispensings were for simvastatin
(47.4%), followed by atorvastatin (28.7%); 80.4% were
lipophilic (Table 1). Statin use before or after diagnosis
was not significantly associated with a reduction in the
hazard of death (adjusted HR before diagnosis 0.88, 95%
confidence interval [CI] 0.58–1.34; adjusted HR after
diagnosis 0.76, 95% CI 0.50–1.61) (Fig. 2, Table S3).
Duration of statin exposure was also not associated with
all-cause mortality (adjusted HR per additional year of sta-
tin use 0.95, 95% CI 0.83–1.09). Neither the amount of
average or cumulative DDDs nor a combination of dura-
tion and dosage changed the HR significantly (Table S4).
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Statistical significant interaction was observed between
statin use and age, gender, unique ATC, and gastrointesti-
nal diseases. Due to low patient numbers, stratification
on unique ATC and gastrointestinal diseases was not
possible and other stratified analyses should therefore be
considered as exploratory. Overall, males have a worse
prognosis than females (HR 1.74, 95% 1.25–2.43). Strati-
fication for gender showed that male statin users have a





(N = 538) P
Gender, N (%)
Male 100 (58.5) 268 (49.8) 0.05
Female 71 (41.5) 270 (50.2)
Age2 (year)
Mean (SD) 67.3 (11.7) 58.0 (16.5) <0.001
Median (IQR) 70 (60–77) 59 (46–70)
Time of FU
Years, median (IQR) 3.5 (1.6–5.8) 2.9 (1.3–5.3) 0.02
Number of deaths N (%) 40 (23.4) 119 (22.1) 0.73
Histological subtype, N (%)
SSM 91 (53.2) 257 (47.8) 0.09
NMM 30 (17.5) 147 (27.3)
LMM 4 (2.3) 8 (1.5)
ALM 2 (1.2) 5 (0.9)
Others 44 (25.7) 121 (22.5)
Body site of the melanoma, N (%)
Head and neck 30 (17.5) 81 (15.1) 0.36
Trunk 65 (38.0) 191 (35.5)
Upper extremity 37 (21.6) 106 (19.7)
Lower extremity 39 (22.8) 160 (29.7)
Tumor thickness, N (%)
≥1.01 and ≤2 83 (48.5) 287 (53.3) 0.39
≥2.01 and ≤ 60 (35.1) 159 (29.6)
≥4.01 28 (16.4) 92 (17.1)
Nodal metastases,2 N (%) 26 (15.2) 78 (14.5) 0.82
Distant metastases,2 N (%) 3 (1.8) 12 (2.2) 1.00
Comorbidities,2 N (%)
Any 105 (61.4) 162 (30.1) <0.001
Hypertension 46 (26.9) 69 (12.8) <0.001
Heart diseases 58 (33.9) 39 (7.2) <0.001
Cancer 32 (18.7) 57 (10.6) 0.01
Stroke 11 (6.4) 7 (1.3) <0.001
Diabetes 22 (12.9) 20 (3.7) <0.001
Lung diseases 10 (5.8) 24 (4.5) 0.22
Gastrointestinal diseases 8 (4.7) 7 (1.3) 0.01
Unique hospitalizations,3 N (%)
No admissions 130 (76.0) 464 (86.2) 0.01
1 admission 31 (18.1) 55 (10.2)
>1 admission 10 (5.8) 19 (3.5)
Unique ATC codes,3 N (%)
0 ATC codes 11 (6.4) 100 (18.6) <0.001
1–3 ATC codes 36 (21.4) 240 (44.6)
>3 ATC codes 124 (72.5) 198 (36.8)
Average DDD, mean (SD) 0.97 (0.55) n.a. n.a.
Average statin exposure in days, mean (SD) 959.8 (882.0) n.a. n.a.
ATC, anatomical therapeutic chemical classification system; FU, follow-up; IQR, interquartile range; N, total number of patients.
1Statin user after melanoma diagnosis.
2At the time of initial melanoma diagnosis.
3In the year prior to diagnosis.
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favorable HR of death (statin use before melanoma: HR
0.62, 95% CI 0.35–1.09, after melanoma diagnosis: HR
0.57, 95% CI 0.32–0.99) compared to male nonusers. In
women, however, there was no effect of statin use (statin
use before melanoma: HR 1.75, 95% CI 0.90–3.38, after
melanoma diagnosis: HR 1.22, 95% CI 0.62–2.38). Fur-
ther stratification according to duration of exposure and
dosage yielded similar results, although all statistically
nonsignificant (Table S4). Stratification on nodal metasta-
ses (yes vs. no) at the time of diagnosis did not show a
significant impact of statin use depending on nodal stage
(data not shown).
Relative survival analyses
The 3-year crude survival of melanoma patients of nonus-
ers and statin users was comparable (80.5% vs. 78.8%,
P = 0.27, Table 3). The 3-year RSR was also comparable
(86.4% vs. 89.4%, P = 0.27, Fig. 3). The 3-year RSR of
randomly selected statin users was better than that of the
general population (105.1%; 95% CI 102.5–107.8).
Stratification for gender showed that male statin users
may have a 3-year RSR superior to the nonusers,
although not statistically significant (91.0% vs. 80.5%,
P = 0.06), whereas no difference of 3-year RSR for female
All statin users
A (N = 110), PY = 373, events = 28
B (N = 171), PY = 555, events = 41
C (N = 171), PY = 555, events = 41
Male statin users
A (N = 65), PY = 220, events = 15
B (N = 100), PY = 319, events = 24
C (N = 100), PY = 319, events = 24
Female statin users
A (N = 45), PY = 153, events = 13
B (N = 71), PY = 236, events = 17
C (N = 71), PY = 236,events = 17
<60 years at diagnosis
A (N = 21), PY = 90, events = 4
B (N = 44), PY = 135, events = 12
>60 years at diagnosis
A (N = 89), PY = 284, events = 24
B (N = 127), PY = 420, events = 29
Hazard ratios of statin use
Hazard ratio
Figure 2. Hazard of death and 95% confidence interval for melanoma patients with statin use compared to nonusers. A = statin use before
melanoma diagnosis. B = statin use after melanoma diagnosis. C = per additional year of use for statin users after melanoma diagnosis. PY,
person years.
Table 3. Three-year crude and relative survival rates for statin users, nonusers, and the matched control cohort.
N Events
Three-year crude
survival KM (%) 95% CI P1
Three-year relative
survival (%) 95% CI P1
Melanoma patients2
Nonuser 599 131 (21.9%) 80.5 77.0–84.0 Referent 86.4 82.6–90.2 Referent
Male 303 90 (29.7%) 74.2 68.7–79.7 Referent 80.5 74.7–86.4 Referent
Female 296 40 (13.5%) 87.3 83.0–91.6 Referent 92.5 87.9–97.0 Referent
Statin user 110 28 (25.5%) 78.8 70.2–87.4 0.27 89.4 80.3–98.5 0.27
Male 65 15 (23.1%) 79.1 67.9–90.3 0.44 91.0 79.3–102.8 0.06
Female 45 13 (28.9%) 78.3 64.8–91.8 0.006 87.1 72.9–101.3 0.76
Matched control cohort3
Statin user 511 42 (8.2%) 94.2 91.8–96.6 n.a. 105.1 102.5–107.8 n.a.
Male 309 30 (9.7%) 93.0 89.6–96.4 n.a. 104.7 100.9–108.5 n.a.
Female 202 12 (5.9%) 96.1 93.0–99.2 n.a. 105.7 102.3–109.1 n.a.
CI, confidence interval; n.a., not applicable.
1Log-rank test for crude survival, z-test for proportions for relative survival.
2Chronic statin users. Minimum 2 dispensings for statin within 1 year prior to melanoma diagnosis and use at time of melanoma diagnosis.
3Control cohort of statin users without melanoma diagnosis matched on age and gender.
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patients was seen (87.1% vs. 92.5%, P = 0.76). These gen-
der differences were not found in the randomly selected
statin users, where 3-year RSR of males and females were
comparable (Table 3).
Discussion
In our cohort of 709 melanoma patients with a Breslow
thickness >1 mm, statin use did not significantly impact
overall survival, but our results indicate that statin use
might lead to differential survival of melanoma patients
depending on gender. Neither timing nor duration or
dosage of statin use changed the hazard of death signifi-
cantly. Stratification on gender, however, demonstrated
possible superior survival of statin users compared to
nonusers in males only.
The currently proposed potential anticancer effects of
statins include the induction of melanoma cell apoptosis,
the inhibition of proliferation and invasion, the preven-
tion of the activation of key proteins for cell cycle regula-
tion, and the stimulation of antimelanoma immune
responses [10–14, 16, 17, 37–42].
Only one other population-based study investigated
statin use and cancer mortality in melanoma among sev-
eral other cancer types [43]. Danish patients using statins
were 15% less likely to die from any cause (HR 0.85, 95%
CI 0.83–0.87) and from cancer (HR 0.85, 95% CI 0.82–
0.87). A reduced cancer-related mortality for statin users
was found in 13 different cancers including lung, colorec-
tal, prostate and breast, but not in melanoma (HR 1.21,
95% CI 0.95–1.52). A subanalysis for gender in melanoma
patients was not performed, but the HR for all cancer
patients and cancer-related mortality showed that the HR
of death in male patients using statins was reduced more
than in female patients (HR 0.82, 95% CI 0.81–0.86 vs.
HR 0.92, 95% CI 0.88–0.92).
The female survival advantage in melanoma in general
was confirmed in our study. The favorable results of statin
use only in male statin users are therefore surprising. Can-
cer survival has been shown to be generally better in
females than in males for most cancers [44], especially in
melanoma [45, 46]. Even after adjustment for potential
behavioral differences (primarily diagnostic delay and
healthcare consumption), sex remains an independent
prognostic factor for melanoma progression and survival
[45]. Biological differences are therefore highly likely to
play a role.
When investigating the 3-year RSR differences across
gender in our study group more closely (Fig. 2, Table S2),
male nonusers have a poor prognosis (80.5%) compared to
either female nonusers (92.5%) or statin users (89.4%).
However, statin use in males improves their prognosis to
levels comparable to female patients (91.0%). Statin use
somehow seems to negate the male survival disadvantage in
melanoma. Therefore the effects of statins on melanoma
might be related to the underlying mechanism of the overall
gender differences in melanoma survival. We suggest two
mechanisms influenced by statins which might be related to
the overall male disadvantage in melanoma survival.
First, Krauthammer et al. [47] reported that somatic
activating Rac1 mutations, ranking third after BRAF- and
NRAS-mutations, in general, occur significantly more often
in men than in women. As statins have been shown to pre-
vent Rac1 isoprenylation [15] and to inhibit the Rho-path-
way [15, 19], it might be possible that males have worse
























All cases Male Female
Non-users Users Controls
Figure 3. Three-year relative survival rate and standard error of the melanoma patients and controls. The relative survival rate of all melanoma
patients and female melanoma patients with statin use was comparable to the nonusers, whereas male statin users may have a 3-year RSR
superior to the nonusers, although not statistically significant (91.0% vs. 80.5%, P = 0.06).
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mutations leading to an increased activity of the Rho-path-
way in male melanoma cells, which in turn might be coun-
teracted by statin use. Second, as melanoma is a highly
immunogenic tumor [48] and males have a weaker
immune system than females [49], it might be possible that
males benefit more from the activating effect of statins on
the antimelanoma immune response [14, 17, 42] than
females, explaining the differential effect of statin use across
gender. However, the noticed gender differences might also
only be an epiphenomena with the underlying cause being
associated with gender but not caused by gender.
The most noteworthy strengths of this study are its
prospective nature and the validated data from two large,
nationally representative and linked cancer- and phar-
macy databases, which provided detailed information on
patient demographics, patient outcomes, tumor character-
istics and, importantly, dose, duration, and timing of sta-
tin exposure.
There are some limitations that need to be addressed.
As the cause of death was unknown, only all-cause rather
than cancer-specific mortality could be assessed. We
therefore calculated RSR as a proxy for disease-specific
survival. With the inclusion of randomly selected statin
users we demonstrated that relative survival of statin users
is better than the general age- and gender-matched popu-
lation. This implies that part of the improved 3-year sur-
vival rate in male melanoma patients with statin use may
also be attributed to a decreased death risk due to cardio-
vascular comorbidities.
We had insufficient data to investigate separately for
lipophilic and hydrophilic statins. Some studies, especially
in breast cancer could only see a positive effect of lipo-
philic statins on in vivo breast cancer recurrence [25, 26]
and in vitro breast cancer growth [50]. Only lipophilic
statins are able to permeate the cell membrane and thus
to directly affect cell proliferation, survival, and motility
[51], hydrophilic statins require active carrier-mediated
uptake, which is only present in hepatocytes. However,
the majority of prescriptions in our cohort were for lipo-
philic statins (80.3%), it can thus be assumed that the
results are primarily attributable to lipophilic rather than
hydrophilic statins.
We had information on important possible confound-
ers, such as cancer stage, comorbidities, and concomitant
drug use. Other possible confounders, such as social and
lifestyle factors (e.g., smoking) were not available through
PHARMO Database Network and could therefore not be
adjusted for. As the study was nonrandomized, residual
confounding cannot be excluded.
In conclusion, our data did not show a significant ben-
eficial effect of statins on survival of melanoma patients.
The differential impact that statin use seems to have on
male and female melanoma patients and possibly also
other tumor entities requires further research in even lar-
ger cohorts and should include measures on cancer-spe-
cific outcomes. Additionally, when in vitro experiments
are conducted, both male and female melanoma cell lines
should be used to see if gender differences can be noticed.
Future studies should also try to address effects of lipo-
philic versus hydrophilic statins.
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